Oxybutynin Chloride Extended-Release Tablet USP, 5 mg, 100 count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. NDC # 68382-255-01
Published November 15, 2023 · Recall initiated: October 19, 2023
Summary
FDA records drug Class II recall D-0096-2024, published November 15, 2023 and initiated October 19, 2023. Recalling firm: Zydus Pharmaceuticals (USA) Inc; Status: Completed; Lot: M212749, exp. date 11/2024; M214477, exp. date 11/2024; M214478, exp. date 11/2024; M214479, exp. date 11/2024; M214480, exp. date 11/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.
What to do
Voluntary: Firm initiated · Letter
Get an email if OXYBUTYNIN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- OXYBUTYNIN
- Manufacturer
- Zydus Pharmaceuticals (USA) Inc
- Distributor
- Nationwide.
- Lot
- M212749, exp. date 11/2024; M214477, exp. date 11/2024; M214478, exp. date 11/2024; M214479, exp. date 11/2024; M214480, exp. date 11/2024
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAOxybutynin Chloride Extended-Release Tablet USP, 15 mg, 100 count bottles, Rx Only, Manufactured by: CadilaNovember 15, 2023
- FDAOxybutynin Chloride Extended-Release Tablet USP, 10 mg, 100 count bottles Rx Only, Manufactured by: CadilaNovember 15, 2023
- FDADeferasirox Tablets for Oral Suspension, 500mg, 30-count bottle, Rx only, Manufactured for: GlenmarkNovember 15, 2023
- FDAOxaydo (oxycodone HCl, USP) tablets, 7.5 mg, 100 Tablets per bottle, Rx only, Distributed by: Zyla LifeNovember 15, 2023
- FDAMycophenolate Mofetil for Oral Suspension, USP, 200 mg/mL, Rx Only, bottle, Manufactured for: VistaPharm,November 15, 2023
- FDAOxybutynin Chloride Extended-Release Tablets USP 10 mg, a) 100 tablets (NDC 68382-256-01) and b) 500 tabletsOctober 11, 2023
Questions about this recall
Was Oxybutynin Chloride Extended-Release Tablet USP, 5 mg, 100 count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Baddi, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. NDC # 68382-255-01 recalled?
Yes. FDA published recall D-0096-2024 on November 15, 2023. Reported hazard: Failed Dissolution Specifications-out-of-specification (OOS) test results observed for dissolution at the 6 month long term time point.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: OXYBUTYNIN.